Quorum IRB Board Chair to Speak at South Korean Research Summit
Quorum Review IRB, the industry leader in central IRB services, announces its Board Chair, Stephen Rosenfeld, MD, MBA, will speak at the 2013 Global Clinical Research Summit to be held Oct. 1 and 2 in Daegu, South Korea.
Seattle, WA (PRWEB) September 17, 2013
Quorum Review IRB, the industry leader in central IRB services, announces its Board Chair, Stephen Rosenfeld, MD, MBA, will speak at the 2013 Global Clinical Research Summit to be held Oct. 1 and 2 in Daegu, South Korea. This year’s gathering will focus on the “Innovative, Integrative and Personalized Care Approach” in worldwide human subject research.
Dr. Rosenfeld’s discussion on Oct. 1 is entitled “CIM Challenge to Global Unique Model as Pioneer” and will cover how to perform rigorous research combining western therapeutic practice and traditional Korean medicine. This will mark the first time a member of the Quorum Review Board presents in Asia since the renowned IRB expanded its services to international markets outside of the U.S. and Canada.
As previously announced, Dr. Rosenfeld was recently appointed to the Secretary’s Advisory Committee on Human Research Protections (SACHRP), an exclusive panel that advises the U.S. Secretary of Health and Human Services in the area of human research subjects. His appearance at the summit is expected to combine the detailed approach he employs as Quorum Review’s Board Chair with that of his broader scope as a SACHRP member who is improving the research oversight process.
Rosenfeld says, “It's an honor to be representing Quorum Review IRB in South Korea at this prestigious event, and I am looking forward to contributing to the international perspective on human clinical research.”
For the latest on Quorum Review News and Events, visit http://www.quorumreview.com.
About Quorum Review IRB
Quorum Review is an independent review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing IRB review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.
Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the United States and internationally, a specialized Phase I team, and unique processes for post-approval and registry studies.
Director, Client Relations & Marketing
Quorum Review IRB
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11115823.htm